Pacira Pharmaceuticals Inc (PCRX) : Gilder Gagnon Howe Co reduced its stake in Pacira Pharmaceuticals Inc by 3.41% during the most recent quarter end. The investment management company now holds a total of 2,140,098 shares of Pacira Pharmaceuticals Inc which is valued at $101,355,041 after selling 75,491 shares in Pacira Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 3, 2016.Pacira Pharmaceuticals Inc makes up approximately 2.03% of Gilder Gagnon Howe Co’s portfolio.
Other Hedge Funds, Including , Riverpark Advisors added PCRX to its portfolio by purchasing 32,624 company shares during the most recent quarter which is valued at $1,545,073. Pacira Pharmaceuticals Inc makes up approx 0.74% of Riverpark Advisors’s portfolio.Macguire Cheswick Tuttle Investment Counsel boosted its stake in PCRX in the latest quarter, The investment management firm added 525 additional shares and now holds a total of 7,560 shares of Pacira Pharmaceuticals Inc which is valued at $358,042. Pacira Pharmaceuticals Inc makes up approx 0.08% of Macguire Cheswick Tuttle Investment Counsel’s portfolio. Barrett Asset Management added PCRX to its portfolio by purchasing 72 company shares during the most recent quarter which is valued at $3,896. Asset Dedication sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 844 shares of PCRX which is valued $45,669.Quadrant Capital Group boosted its stake in PCRX in the latest quarter, The investment management firm added 16 additional shares and now holds a total of 96 shares of Pacira Pharmaceuticals Inc which is valued at $5,195.
Pacira Pharmaceuticals Inc opened for trading at $48.71 and hit $50 on the upside on Tuesday, eventually ending the session at $49.59, with a gain of 2.35% or 1.14 points. The heightened volatility saw the trading volume jump to 7,45,536 shares. Company has a market cap of $1,843 M.
On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.09. The company had revenue of $65.50 million for the quarter, compared to analysts expectations of $66.82 million. The company’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Shares were Reiterated by Mizuho on May 3, 2016 to “Buy” and Lowered the Price Target to $ 64 from a previous price target of $71 .Mizuho Initiated Pacira Pharmaceuticals Inc on Apr 19, 2016 to “Buy”, Price Target of the shares are set at $79.
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.